IDT Biologika Receives Six 2019 CMO Leadership Awards

DESSAU, Germany & ROCKVILLE, Md.–(BUSINESS WIRE)–IDT Biologika, a globally integrated contract manufacturer of vaccines
and biopharmaceuticals, honored with six 2019 CMO Leadership Awards in
all categories, including Capabilities, Compatibility, Expertise,
Quality, Reliability and Service. Sponsored by Life Science Leader
magazine, the annual awards recognize the top contract manufacturing
organizations (CMOs) serving the pharmaceutical and biopharmaceutical
industries.

IDT Biologika Chief Executive Officer Dr. Jürgen Betzing accepted the
2019 CMO Leadership Awards on behalf of the company. “With our wide
range of innovative technologies, experience and competence in
biopharmaceutical development and production, we advance our clients’
biopharmaceutical products to prevent and treat diseases that impact the
health of people worldwide. IDT is a valued partner for all
organizations working to bring new vaccines and biopharmaceutical
products to patients,” said Dr. Betzing. “The success of our customers
is highlighted by honors in each of the six categories of the CMO award
in which we are decorated this year. We are a true partner,
offering our customers seamless end-to-end solutions to meet all of
their vaccines and biologics needs. Together, we can combat diseases and
epidemics worldwide.”

Winners were evaluated based on real-world experiential data and
feedback from decision makers who work with contract manufacturing
suppliers. IDT was judged by its customers as a top performer among more
than 120 CMOs. The company achieved this high honor in six of six
categories across 23 performance metrics considered important to the
selection of a CMO and based on customers’ direct experience working
with IDT on an outsourced project within the last 18 months. Life
Science Leader teamed up with Industry Standard Research (ISR) to
conduct the Contract Manufacturing Quality Benchmarking survey
that captured input from decision makers.

The award adds to IDT’s distinguished reputation in the contract
services business and celebrates the company’s ongoing commitment to
manufacturing excellence. Today, IDT offers a wide range of services
during all phases of vaccine and biopharmaceutical development – from
early research and process development through clinical and commercial
manufacturing.

For more information, visit IDT Biologika at www.idt-biologika.com.

About IDT Biologika

IDT Biologika is an innovative, privately-held company with nearly 100
years of experience in researching, developing, manufacturing and
marketing products for the global protection of human and animal health.
The company produces vaccines and pharmaceuticals according to the
highest quality standards, for its own animal health products and under
contract.

Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and
the Riems district of Greifswald. IDT’s Animal Health business is
marketed internationally from its offices in Denmark, the Netherlands,
France, Spain, Poland and Canada. In the United States, IDT Corporation
operates a production site for clinical test samples in Rockville,
Maryland. In Canada, IDT Biologika subsidiary Gallant Custom
Laboratories manufactures autogenous vaccines. The same vaccines are
produced by the recently acquired IDT subsidiary in the United Kingdom,
Ridgeway Biologicals.

IDT Biologika is a member of the Klocke Group, which is specialized in
contract production and packaging of medications, vaccines and cosmetic
products. As a traditional family-owned company, the Klocke Group
employs a workforce of more than 2,500 people at eight production sites
and sales offices around the world. For more information, visit www.idt-biologika.com.

Contacts

IDT Biologika Corporate Communications
Christian Herschel
Am
Pharmapark
06861 Dessau-Roßlau
Tel: +49 34901 885 4293
Mob.
+49 162 1011442
Email: [email protected]
Web:
www.idt-biologika.com

Mike Beyer
Sam Brown Inc.
Tel: 312-961-2502
Email: [email protected]